Nektar Therapeutics
NASDAQ:NKTR
Nektar Therapeutics
NASDAQ:NKTR
Price:
1.83 USD
3.39%
Updated:
May 16, 2024
Nektar Therapeutics
Research & Development
|
Nektar Therapeutics
Research & Development Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Nektar Therapeutics
NASDAQ:NKTR
|
Research & Development
-$111.2m
|
CAGR 3-Years
34%
|
CAGR 5-Years
23%
|
CAGR 10-Years
5%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Research & Development
-$15.2B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-6%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Research & Development
-$9.3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-10%
|
|
|
Pfizer Inc
NYSE:PFE
|
Research & Development
-$10.6B
|
CAGR 3-Years
-74%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-5%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Research & Development
-$29.5B
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-15%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Research & Development
-$9.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-6%
|
See Also
What is Nektar Therapeutics's Research & Development?
Research & Development
-111.2m
USD
-111.2m
USD
Based on the financial report for Mar 31, 2024, Nektar Therapeutics's Research & Development amounts to -111.2m USD.
What is Nektar Therapeutics's Research & Development growth rate?
Research & Development CAGR 10Y
5%
5%
Over the last year, the Research & Development growth was 21%. The average annual Research & Development growth rates for Nektar Therapeutics have been 34% over the past three years , 23% over the past five years , and 5% over the past ten years .
You don't have any saved screeners yet
